Form 4: Cytokinetics EVP Plans Future Stock Sale for Tax

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, has filed a Form 4 reporting a planned sale of 2,058 shares of common stock on December 3, 2025, to cover tax withholding obligations related to PSUs vested in December 2024.

Summary

• Fady Ibraham Malik, Executive Vice President of Research & Development at Cytokinetics Inc. (CYTK), reported a planned transaction.
• The transaction involves the disposition of 2,058 shares of Cytokinetics Common Stock.
• The planned transaction date is December 3, 2025.
• The shares will be sold at a price of $65.02 per share.
• This sale is a 'sell to cover' transaction for tax withholding purposes, related to Performance Stock Units (PSUs) that were granted on March 14, 2024, and earned (vested) on December 2, 2024.
• Following this planned transaction, Fady Ibraham Malik will beneficially own 138,552 shares of Common Stock directly.
• The transaction is being made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned 'sell to cover' transaction for tax purposes, which is a neutral event and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

The filing indicates a pre-planned future transaction for tax purposes, which is a routine event related to executive compensation and does not provide specific forward-looking guidance on company performance or strategy.

Industry Context

This is a routine insider transaction filing common across all industries, reflecting an executive's management of equity compensation for tax obligations. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, pre-planned transaction for tax purposes and not a discretionary sale indicating a change in management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Tax Withholding, Performance Stock Units, 10b5-1 Plan